Sarah Chaney gives an in-depth look at the Salix-Valeant acquisition - how analysts and investors can affect decision-making and potentially drive poor behavior.
Sarah Chaney
Advertisement
Sarah Chaney is a business reporting student at the University of North Carolina at Chapel Hill.
Articles by Sarah Chaney
Advertisement
Latest Updated Articles
- The Salix-Valeant Acquisition: "It’s Just a Game"
July 7th 2015
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
2
Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somnivera
3
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
4
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
5